# Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Leukemia or Lymphoma Undergoing Stem Cell Transplantation

> **NCT03856216** · PHASE2 · TERMINATED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 15 (actual)

## Conditions studied

- Acute Lymphoblastic Leukemia
- B Acute Lymphoblastic Leukemia
- Lymphocytic Neoplasm
- Lymphoma

## Interventions

- **PROCEDURE:** Allogeneic Bone Marrow Transplantation
- **DRUG:** Bendamustine
- **BIOLOGICAL:** Filgrastim-sndz
- **DRUG:** Fludarabine
- **BIOLOGICAL:** Inotuzumab Ozogamicin
- **DRUG:** Melphalan
- **PROCEDURE:** Peripheral Blood Stem Cell Transplantation
- **BIOLOGICAL:** Rituximab
- **DRUG:** Tacrolimus

## Key facts

- **NCT ID:** NCT03856216
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-10-28
- **Primary completion:** 2025-10-13
- **Final completion:** 2025-10-13
- **Target enrollment:** 15 (ACTUAL)
- **Why stopped:** \<75% participation
- **Last updated:** 2026-04-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03856216

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03856216, "Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Leukemia or Lymphoma Undergoing Stem Cell Transplantation". Retrieved via AI Analytics 2026-07-12 from https://api.ai-analytics.org/clinical/NCT03856216. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*